001     303359
005     20250810021935.0
024 7 _ |a 10.1007/s00401-025-02917-z
|2 doi
024 7 _ |a pmid:40751809
|2 pmid
024 7 _ |a 0001-6322
|2 ISSN
024 7 _ |a 1432-0533
|2 ISSN
024 7 _ |a altmetric:180083392
|2 altmetric
037 _ _ |a DKFZ-2025-01609
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Keck, Michaela-Kristina
|0 P:(DE-He78)9f1196ab1abb80483e1f69e8c0c4172d
|b 0
|e First author
|u dkfz
245 _ _ |a PLAG1 fusions define a third subtype of CNS embryonal tumor with PLAG family gene alteration.
260 _ _ |a Heidelberg
|c 2025
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1754300059_1226
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:B360#LA:B360#LA:B300#
520 _ _ |a CNS embryonal tumors with PLAGL amplification (ET, PLAGL) are a recently described tumor type marked by amplification of one of the PLAG family genes, PLAGL1 or PLAGL2. Separately, a supratentorial, ependymoma-like CNS tumor type with PLAG family alteration, namely PLAGL1 fusion, was also reported (NET_PLAGL1). Here, we use DNA methylation profiling in combination with copy number, RNA-seq, and histological analysis to characterize and classify a novel group of CNS embryonal tumors harboring PLAG1 gene fusions (n=12). Through our screening, we identified a subset of CNS tumors (n=12) epigenetically distinct from other known CNS tumor types, but clustering close to the PLAGL1- and PLAGL2-amplified ET, PLAGL subtypes in our t-SNE analysis. Copy number profiles indicated putative PLAG1 fusions, which were confirmed in 9/12 tumors (not determined in 3/12). Different 5' fusion partners (ASAP1, ADGRG1, TMEM68, TCF4, CHD7, NCALD, HNRNPK, LOC105378102) were identified that upregulate wild-type PLAG1 through promoter hijacking. Expression analysis shows upregulation of PLAG1 as well as IGF2, DLK1, Desmin, CYP2W1, and RET, which are also robustly expressed in PLAGL1/2-amplified tumors. Patient characteristics, survival data, and clinical/imaging analysis show additional similarities to PLAGL1/2-amplified tumors. Median age at diagnosis was 5 years, tumors were located throughout the neuroaxis, and original histological diagnoses were heterogeneous. The tumors demonstrated morphologic heterogeneity, with most composed of densely cellular areas of primitive small blue cells, alongside focal regions showing clear cell morphology, microcystic changes, and ependymoma-like perivascular pseudorosettes. Applied treatment regimens were also heterogeneous, but some favorable responses to therapy were observed. In summary, we describe a third subtype of PLAG family-altered pediatric CNS embryonal tumor characterized by PLAG1 gene fusion, which leads to upregulation of PLAG1 and downstream genes. We therefore propose to rename ET, PLAGL to ET, PLAG (CNS embryonal tumor with PLAG family gene alteration) together with a specification of the respective subtype.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a PLAG1
|2 Other
650 _ 7 |a PLAG1 fusion
|2 Other
650 _ 7 |a PLAGL1
|2 Other
650 _ 7 |a PLAGL2
|2 Other
650 _ 7 |a Embryonal CNS tumor
|2 Other
650 _ 7 |a PLAG1 protein, human
|2 NLM Chemicals
650 _ 7 |a DNA-Binding Proteins
|2 NLM Chemicals
650 _ 7 |a Transcription Factors
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a DNA-Binding Proteins: genetics
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Central Nervous System Neoplasms: genetics
|2 MeSH
650 _ 2 |a Central Nervous System Neoplasms: pathology
|2 MeSH
650 _ 2 |a Neoplasms, Germ Cell and Embryonal: genetics
|2 MeSH
650 _ 2 |a Neoplasms, Germ Cell and Embryonal: pathology
|2 MeSH
650 _ 2 |a Child
|2 MeSH
650 _ 2 |a Child, Preschool
|2 MeSH
650 _ 2 |a Transcription Factors: genetics
|2 MeSH
650 _ 2 |a Adolescent
|2 MeSH
650 _ 2 |a Gene Fusion
|2 MeSH
700 1 _ |a Al-Hussaini, Maysa
|b 1
700 1 _ |a Amayiri, Nisreen
|b 2
700 1 _ |a Yiadom, Akosua Adoma Boakye
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Chamyan, Gabriel
|b 4
700 1 _ |a Cheesman, Edmund
|b 5
700 1 _ |a Faure-Conter, Cécile
|b 6
700 1 _ |a Garcia-Ariza, Miguel
|b 7
700 1 _ |a Gauchotte, Guillaume
|b 8
700 1 _ |a Hasselblatt, Martin
|b 9
700 1 _ |a Jorgensen, Mette
|b 10
700 1 _ |a Kilday, John-Paul
|b 11
700 1 _ |a Lamas, Gabriela
|b 12
700 1 _ |a Lavarino, Cinzia
|b 13
700 1 _ |a Li, Marilyn M
|b 14
700 1 _ |a Lubieniecki, Fabiana
|b 15
700 1 _ |a Maher, Ossama M
|b 16
700 1 _ |a Meyronet, David
|b 17
700 1 _ |a Mueller, Jan
|0 P:(DE-HGF)0
|b 18
700 1 _ |a Santi, Mariarita
|b 19
700 1 _ |a Schüller, Ulrich
|b 20
700 1 _ |a Seidinger, Ana Luiza
|b 21
700 1 _ |a Sill, Martin
|0 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
|b 22
|u dkfz
700 1 _ |a Sudhakar, Sniya
|b 23
700 1 _ |a García, María Tallón
|b 24
700 1 _ |a Tauziede-Espariat, Arnault
|b 25
700 1 _ |a Varlet, Pascale
|b 26
700 1 _ |a Vasiljevic, Alexandre
|b 27
700 1 _ |a Wittmann, Andrea
|0 P:(DE-He78)adf0bc22f6c87d09ddb939645a7870ed
|b 28
|u dkfz
700 1 _ |a von Deimling, Andreas
|0 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
|b 29
|u dkfz
700 1 _ |a Solomon, David A
|b 30
700 1 _ |a Sahm, Felix
|0 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
|b 31
|u dkfz
700 1 _ |a Tietze, Anna
|b 32
700 1 _ |a von Hoff, Katja
|b 33
700 1 _ |a Sievers, Philipp
|0 P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6
|b 34
|e Last author
|u dkfz
700 1 _ |a Jones, David
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 35
|e Last author
|u dkfz
773 _ _ |a 10.1007/s00401-025-02917-z
|g Vol. 150, no. 1, p. 12
|0 PERI:(DE-600)1458410-4
|n 1
|p 12
|t Acta neuropathologica
|v 150
|y 2025
|x 0001-6322
909 C O |o oai:inrepo02.dkfz.de:303359
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)9f1196ab1abb80483e1f69e8c0c4172d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 28
|6 P:(DE-He78)adf0bc22f6c87d09ddb939645a7870ed
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 29
|6 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 31
|6 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 34
|6 P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 35
|6 P:(DE-He78)551bb92841f634070997aa168d818492
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2025
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-11
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-11
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-11
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ACTA NEUROPATHOL : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-11
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-11
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ACTA NEUROPATHOL : 2022
|d 2024-12-11
920 2 _ |0 I:(DE-He78)B360-20160331
|k B360
|l Pädiatrische Gliomforschung
|x 0
920 2 _ |0 I:(DE-He78)B300-20160331
|k B300
|l KKE Neuropathologie
|x 1
920 1 _ |0 I:(DE-He78)B360-20160331
|k B360
|l Pädiatrische Gliomforschung
|x 0
920 1 _ |0 I:(DE-He78)B300-20160331
|k B300
|l KKE Neuropathologie
|x 1
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 2
920 0 _ |0 I:(DE-He78)B360-20160331
|k B360
|l Pädiatrische Gliomforschung
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B360-20160331
980 _ _ |a I:(DE-He78)B300-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21